Limited coverage drugs – tofacitinib (for rheumatoid arthritis)

Last updated on September 27, 2024

Generic name

tofacitinib

Strength

5 mg, 11 mg

Form

tablet and extended-release tablet

Special Authority criteria

Approval period

For the treatment of rheumatoid arthritis when tofacitinib is prescribed by a rheumatologist according to established criteria, as noted in eForms submission (and on the Special Authority forms linked below). Tofacitinib is to be used in combination with methotrexate, or without methotrexate in patients who are intolerant to methotrexate

First approval: 1 year

Renewal: 1 year or indefinite

Practitioner exemptions

  • None

Special notes

  1. PharmaCare covers a maximum 30 days' supply per fill
  2. PharmaCare coverage is limited to 5 mg of tofacitinib twice daily, or one 11 mg tablet once daily

Special Authority requests